- Home
- ICU vs TLPH Comparison
ICU vs TLPH Comparison
Compare ICU & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICU
- TLPH
- Stock Information
- Founded
- ICU 2018
- TLPH 2005
- Country
- ICU United States
- TLPH United States
- Employees
- ICU N/A
- TLPH N/A
- Industry
- ICU Biotechnology: Pharmaceutical Preparations
- TLPH Biotechnology: Pharmaceutical Preparations
- Sector
- ICU Health Care
- TLPH Health Care
- Exchange
- ICU Nasdaq
- TLPH Nasdaq
- Market Cap
- ICU 9.5M
- TLPH 10.6M
- IPO Year
- ICU N/A
- TLPH 2011
- Fundamental
- Price
- ICU $0.66
- TLPH $0.40
- Analyst Decision
- ICU
- TLPH Strong Buy
- Analyst Count
- ICU 0
- TLPH 1
- Target Price
- ICU N/A
- TLPH $6.00
- AVG Volume (30 Days)
- ICU 5.7M
- TLPH 944.2K
- Earning Date
- ICU 08-12-2025
- TLPH 08-13-2025
- Dividend Yield
- ICU N/A
- TLPH N/A
- EPS Growth
- ICU N/A
- TLPH N/A
- EPS
- ICU N/A
- TLPH N/A
- Revenue
- ICU $428,000.00
- TLPH $27,000.00
- Revenue This Year
- ICU $754.07
- TLPH N/A
- Revenue Next Year
- ICU $100.09
- TLPH $14,533.26
- P/E Ratio
- ICU N/A
- TLPH N/A
- Revenue Growth
- ICU N/A
- TLPH N/A
- 52 Week Low
- ICU $0.31
- TLPH $0.38
- 52 Week High
- ICU $9.09
- TLPH $1.19
- Technical
- Relative Strength Index (RSI)
- ICU 45.72
- TLPH 39.02
- Support Level
- ICU $0.53
- TLPH $0.38
- Resistance Level
- ICU $0.94
- TLPH $0.46
- Average True Range (ATR)
- ICU 0.10
- TLPH 0.03
- MACD
- ICU 0.01
- TLPH -0.00
- Stochastic Oscillator
- ICU 30.91
- TLPH 24.89
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.